Internalizing ErbB2 Antibodies
AssigneeThe Regents of the University of California
InventorsJames D. D. Marks, Marie Alix Poul
Life of this patent
Estimating the term…
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Claims22
1-54. (canceled)
A single-chain variable fragment (scFv) antibody, wherein the antibody comprises each of three light chain variable region CDRs and each of three heavy chain variable region CDRs of F5 antibody as encoded by ATCC plasmid deposit designation PTA-7843.
Dependencies are inferred from the claim text.